Ankial Overview
- Year Founded
-
2023
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
Ankial General Information
Description
Developer of a mitochondria activator designed to prevent, slow down, or treat hypertrophic cardiomyopathy in children. The company develops an orphan drug to treat heart disease with a mitochondrial component, enabling pediatric patients to get the treatment of mitochondrial diseases.
Contact Information
Website
ankial-pharma.comCorporate Office
- Bordeaux
- France
Corporate Office
- Bordeaux
- France
Ankial Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 26-May-2026 | Completed | Out of Business | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | 01-Jan-2023 | $21.2K | $21.2K | Completed | Startup |
Ankial Signals
Ankial FAQs
-
When was Ankial founded?
Ankial was founded in 2023.
-
Where is Ankial headquartered?
Ankial is headquartered in Bordeaux, France.
-
What is the size of Ankial?
Ankial has 2 total employees.
-
What industry is Ankial in?
Ankial’s primary industry is Drug Discovery.
-
Is Ankial a private or public company?
Ankial is a Private company.
-
What is Ankial’s current revenue?
The current revenue for Ankial is .
-
How much funding has Ankial raised over time?
Ankial has raised $21.2K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process